An Example of Motivational Interviewing
Fixed-dose combination therapy in type 2 diabetes mellitus.
Blonde L, San Juan ZT, Bolton P. Endocr Pract. 2014;20(12):1322-1332.
From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.
Defronzo RA. Diabetes. 2009;58(4):773-795.
Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
Goring S, Hawkins N, Wygant G, et al. Diabetes Obes Metab. 2014;16(5):433-442.
American Association of Clinical Endocrinologists and American College of Endocrinology—Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015.
Handelsman Y, Bloomgarden ZT, Grunberger G, et al. Endocr Pract. 2015;21(suppl 1):1-87.
Minimizing hypoglycemia in diabetes.
International Hypoglycemia Study Group. Diabetes Care. 2015;38(8):1583-1591.
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Diabetes Care. 2015;38(1):140-149.
The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Kawalec P, Mikrut A, Łopuch S. Diabetes Metab Res Rev. 2014;30(4):269-283.
Changing trends in type 2 diabetes mellitus treatment intensification. 2002-2010.
McCoy RG, Zhang Y, Herrin J, et al. Am J Manag Care. 2015;21(5):e288-e296.
Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis.
Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Diabetes Obes Metab. 2014;16(5):410-417.
The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.
Tschope D, Hanefeld M, Meier JJ, et al.Cardiovasc Diabetol. 2013;12:62.
Standards of medical care in diabetes—2015.
The ADA’s Standards of Care provide clinicians, patients, researchers, payers, and other interested individuals with the components of good diabetes management, general treatment goals, and tools to evaluate the quality of care. Importantly, these recommendations should be adjusted based on individual preferences, comorbidities, and other patient-related factors.
American Diabetes Association. Diabetes Care. 2015;38(suppl 1):S1-S94.
AACE/ACE comprehensive diabetes management algorithm 2015.
This algorithm from the AACE addresses evaluating the whole patient, potential risks and complications, and evidence-based treatment approaches for diabetes. The document contains sections on obesity, prediabetes, hyperglycemia therapy (lifestyle modifications, pharmacotherapy, and insulin), hypertension management, hyperlipidemia treatment, and other risk-reduction strategies.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Endocr Pract. 2015;21(4):438-447.
Provides easy access to resources to help patients live well and meet their goals—whether they have diabetes or are at risk for the disease.